Eli Lilly shares slide premarket on news of failed trial for sarcoma treatment [MarketWatch]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: MarketWatch
Eli Lilly shares slide premarket on news of failed trial for sarcoma treatment Eli Lilly and Co. shares LLY, +2.02% fell as much as 5% in premarket trde Friday before paring those losses, after the company said a late-stage trial of a treatment for sarcoma failed to meet its main goals. The phase 3 trial of Lartruvo in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS) did not meet its primary endpoint of overall survival. It had previously shown an overall survival benefit in a 133-patient phase 2 trial which led to accelerated approval by the U.S. Food and Drug Administration and the European Medicines Agency. The company "was surprised and disappointed that LARTRUVO did not improve survival for patients with advanced soft tissue sarcoma in this study," said Anne White, president, Lilly Oncology, in a statement. The company is in talks with global regulators to determine its next steps. In the meantime, it expects to book a charge of $7
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly's Q1 [Forbes]Forbes
- Global CDK 4/6 Inhibitor Drugs Market Outlook 2023-2035: A USD 66.63 Billion Market by 2035, Up From USD 9.03 Billion in 2022 [Yahoo! Finance]Yahoo! Finance
- Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics [Yahoo! Finance]Yahoo! Finance
- American Kidney Fund Launches National Kidney Health Equity Media Campaign [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk comes under Senate probe over pricing for weight loss drugs [Seeking Alpha]Seeking Alpha
LLY
Earnings
- 2/6/24 - Miss
LLY
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- LLY's page on the SEC website